IFN-antagonist function is a major determinant of pathogenicity and cross-species infection by viruses, but remains poorly defined for many potentially zoonotic viruses resident in animal species. The paramyxovirus family contains several zoonotic viruses, including highly pathogenic viruses such as Nipah virus and Hendra virus, and an increasing number of largely uncharacterized animal viruses. Here, we report the characterization of IFN antagonism by the rodent viruses J virus (JPV) and Beilong virus (BeiPV) of the proposed genus Jeilongvirus of the paramyxoviruses. Infection of cells by JPV and BeiPV was found to inhibit IFN-activated nuclear translocation of signal transducer and activator of transcription 1 (STAT1). However, in contrast to most other paramyxoviruses, the JPV and BeiPV V proteins did not interact with or inhibit signalling by STAT1 or STAT2, suggesting that JPV/BeiPV use an atypical V proteinindependent strategy to target STATs, consistent with their inclusion in a separate genus. Nevertheless, the V proteins of both viruses interacted with melanoma differentiation-associated protein 5 (MDA5) and robustly inhibited MDA5-dependent activation of the IFN-b promoter. This supports a growing body of evidence that MDA5 is a universal target of paramyxovirus V proteins, such that the V-MDA5 interaction represents a potential target for broad-spectrum antiviral approaches.
INTRODUCTION
The subfamily Paramyxovirinae of the family Paramyxoviridae of negative-sense ssRNA viruses contains significant human pathogens, including the species Measles virus and Nipah virus, in addition to a number of largely uncharacterized viruses identified in animals. Among the latter are the species J virus and Beilong virus, which are suggested to form a distinct genus, Jeilongvirus (Jack et al., 2005; Li et al., 2006; Magoffin et al., 2007) . Current data indicate that Beilong virus (BeiPV) and J virus (JPV) are of rodent origin (Jun et al., 1977; Li et al., 2006; Woo et al., 2012) , but BeiPV was discovered in a human kidney cell line (Li et al., 2006) and neutralizing antibodies against JPV have been detected in rodents, pigs and humans (Jun et al., 1977) , suggestive of broad host range and possible zoonotic potential.
The type I IFN (IFN-a/b)-mediated innate immune response is a major barrier to cross-species/zoonotic infection such that viral capacity to surmount this response is considered a determinant of invasive potential. Initiation of the response follows detection of infection by cellular receptors such as the cytoplasmic helicase melanoma differentiation-associated protein 5 (MDA5), which can detect RNA genome replication within infected cells (Akira, 2009; Medzhitov, 2007) . Receptor activation ultimately leads to the phosphorylation and nuclear translocation of the transcription factors interferon regulatory factor (IRF)-3/IRF-7, which then activate promoters of type I IFN genes to trigger transcription (Yie et al., 1999) .
Type I IFNs are secreted from infected cells and signal in autocrine or paracrine fashion, binding to the IFN-a/b receptor (IFNAR). This leads to phosphorylation of the transcription factors signal transducers and activators of transcription (STATs) 1 and 2 by IFNAR-associated janus kinases JAK1 and Tyk2, respectively. Phosphorylated STATs (p-STATs) 1 and 2 form heterodimers that enter the nucleus and bind to IFN-sensitive response elements (ISRE) in the promoters of IFN-stimulated genes (ISGs) (Randall & Goodbourn, 2008) . The resulting induction of ISG expression leads to the establishment of an antiviral state.
Viral suppression of the IFN response is mediated through the function of proteins called viral IFN antagonists. Paramyxoviruses are well characterized in this respect, with IFN antagonism commonly mediated by the accessory V protein, which is encoded within the P genes of almost all paramyxovirus species (Audsley & Moseley, 2013) . All V proteins examined have the conserved ability to interact with MDA5, wherein conserved cysteine residues in the V protein C-terminal domain (V-CTD; Fig. S1 , available in the online Supplementary Material) interact with the helicase region of MDA5 to prevent activation of downstream pathways to IFN transcription (Andrejeva et al., 2004; Ramachandran & Horvath, 2010) . All paramyxovirus V proteins tested have also been found to interact with host STAT1 and/or STAT2, albeit to differing extents, depending on the virus species/strain (Audsley & Moseley, 2013; Chinnakannan et al., 2013; and see below) . These interactions appear to use different regions/residues from those involved in MDA5 interaction (Audsley & Moseley, 2013) and there is no conserved STAT-binding site in the subfamily, with the regions involved varying significantly between genera/species (Fig. S1 ).
Mechanisms of STAT inhibition by V are generally conserved within each genus, and include sequestering STAT1/2 in high molecular mass complexes in the cytoplasm (genus Henipavirus), inhibiting STAT1/2 nuclear translocation with or without affecting phosphorylation (genus Morbillivirus), and targeting STAT1 or STAT2 for proteasomal degradation (most members of the genus Rubulavirus) (Andrejeva et al., 2002; Kubota et al., 2001; Nanda & Baron, 2006; Palosaari et al., 2003; Rodriguez et al., 2002 Rodriguez et al., , 2003 Röthlisberger et al., 2010) . These mechanisms are generally considered to relate to interaction of V protein with STATs, but recent data indicate that inhibition of STAT phosphorylation by certain morbillivirus V proteins involves targeting of Tyk2/JAK1 (Chinnakannan et al., 2013) .
In spite of a significant body of data describing IFN antagonism by established paramyxoviruses, the expression of V protein and modes of immune evasion used by many newly identified paramyxoviruses, including those of the proposed genus Jeilongvirus, have not been determined. Here we showed that JPV and BeiPV produce V protein transcript during infection, and that JPV and BeiPV V proteins inhibit MDA5-dependent signalling. Notably, we also found that, although JPV and BeiPV can inhibit STAT1 responses to IFN-a in infected cells, this does not appear to involve the V proteins. This is to the best of our knowledge the first characterization of JPV/BeiPV IFN-antagonist function, and indicates that the immune evasion strategies of these viruses are distinct from other paramyxoviruses examined, further supporting their proposed classification within a separate genus.
RESULTS AND DISCUSSION
JPV and BeiPV produce transcripts encoding V protein
In most paramyxovirus genera, faithful transcription of the P gene generates P protein, an essential cofactor of the viral RNA-dependent RNA polymerase (RdRp). V is usually generated by editing of the P gene mRNA by the RdRp, which inserts non-templated G nucleotides at a predetermined site. JPV and BeiPV P genes contain a putative editing site (Jack et al., 2005; Li et al., 2006) , where insertion of one or two nucleotides would generate transcripts encoding V and W proteins, respectively. To determine whether JPV and BeiPV produce edited P gene mRNA, we analysed transcripts from cells infected with JPV or BeiPV, as well as cells infected with rubulaviruses Menangle virus (MenPV) or Mapuera virus (MprPV), which use a distinct P gene editing strategy (Fig. 1a) .
The majority of reads for all viruses corresponded to non-edited transcripts, encoding P protein (P-mRNA) in JPV/BeiPV or V protein (V-mRNA) in MenPV/MprPV (Fig. 1b) . Of transcripts from JPV and BeiPV, 11.1 and 8.2 % respectively, contained one additional G nucleotide (+G), corresponding to V-mRNA (Fig. 1b) . JPV and BeiPV transcripts corresponding to W-mRNA (+GG) occurred with a frequency comparable to that observed for the rubulavirus W-mRNA (+G). MenPV editing frequency (Fig. 1b) was consistent with findings of a previous study sequencing cDNA clones (Bowden et al., 2001) . No other regions within the P gene sequences contained insertion/deletion of more than one nucleotide, and quality reports confirmed that reads were of high quality (25 % quartile Phred scores i20, 99 % base call accuracy), indicating that our approach using Illumina sequencing by synthesis technology represents a robust method to monitor editing.
Consistent with these findings, a previous study by Li et al. (2006) found that antibody against the shared N-terminal region of BeiPV P/V/W can recognize full-length P protein and smaller species of *45 kDa, corresponding to V/W. Although a lack of cross-reactivity of the BeiPV antibody precluded analysis of JPV, we could confirm the presence of these species in BeiPV-infected cell lysates by Western blot analysis (data not shown; see Li et al., 2006) . Together, these data indicate that JPV/BeiPV edit their P gene transcripts to generate mRNA encoding V protein. ( Audsley & Moseley, 2013 Confocal laser scanning microscopy (CLSM) analysis of JPV-infected cells fluorescently immunostained using antiserum raised against the whole JPV virus indicated largely punctate staining in the cytoplasm (Fig. 2a) . Immunostaining of BeiPV-infected cells with anti-BeiPV P/V/W antibody (see above) labelled the nucleus and cytoplasm (Fig. 2b) , consistent with the nucleocytoplasmic localization of BeiPV V protein alone (see below).
STAT1 immunostaining indicated predominantly cytoplasmic localization in all cell samples in the absence of IFN treatment ( Fig. 2a, b ). IFN-a treatment of mock-infected cells resulted in nuclear accumulation of STAT1 as expected, but in JPV and BeiPV-infected cells this was clearly impaired (Fig. 2a, b) . To quantify STAT1 nucleocytoplasmic localization, we determined the ratio of nuclear to cytoplasmic fluorescence (F n/c ) (Oksayan et al., 2012b; Wiltzer et al., 2014) . This indicated that STAT1 nuclear localization in IFN-a-treated cells was significantly reduced in JPV-and BeiPV-infected cells (Pv0.0001 and P50.0002, respectively) compared with mock-infected cells (Fig. 2c, d ). Thus, STAT1 responses to IFN-a are strongly impaired by JPV or BeiPV infection.
JPV and BeiPV V proteins do not inhibit nuclear translocation of IFN-a-activated STATs
To examine whether JPV/BeiPV antagonism of STAT1 is a function of V protein, we expressed V proteins fused at Images such as those shown were used to determine the nuclear : cytoplasmic fluorescence ratio (F n/c ) for STAT1 (mean F n/c ¡SE, n$25 cells from samples infected in triplicate). All data are representative of two or more independent assays. Statistical analysis used a two-tailed, two-sample unequal variance t-test. **P,0.01; ***P,0.001; ****P,0.0001.
their N terminus to GFP, in COS-7 cells. Transfected cells were treated with or without IFN before analysis of STAT1 and -2 localization by CLSM, as above. As expected, the control V proteins from Nipah virus (NiV) and Hendra virus (HeV), of the closely related genus Henipavirus, significantly (Pv0.0001) inhibited nuclear localization of STAT1 (Fig. 3a , b) and STAT2 ( Fig. 3c, d ) in IFN-treated cells. However, in contrast to JPV/BeiPV infection, expression of JPV or BeiPV V protein alone did not affect the localization of STAT1 (Fig. 3a , b) or STAT2
( Fig. 3c, d ). Thus, the V proteins of JPV and BeiPV differ significantly from those of the henipaviruses as they do not appear to impair IFN-dependent activation or nuclear translocation of STAT1/2, and so are unlikely to be responsible for the effects observed in infected cells (Fig. 2) . The CLSM images also did not indicate any effect of the proteins on the expression of STAT1/2, and Western blot analysis of cell lysates confirmed equivalent expression between transfected populations (Fig. S2) , suggesting that JPV/BeiPV V proteins do not effect STAT degradation. The lack of an effect of JPV or BeiPV V proteins on the localization of STAT1/2 implied either that they do not interact with either of these STATs (making them unique among V proteins examined), or that they can interact but do not significantly affect localization owing to the distribution of the V protein to both the cytoplasm and nucleus (Fig. 3a, c) . To assess interaction of JPV/BeiPV V proteins with STAT1/2, we immunoprecipitated GFPfused V proteins from transfected HEK293T cells for analysis by Western blotting. Both STATs co-precipitated with NiV V, but not with the negative control NiV V-CTD (Fig. 4a) , which lacks the N-terminal STAT1/2 binding site (see Fig. S1 ). STAT1 and STAT2 also could not be detected in immunoprecipitates of JPV V or BeiPV V (Fig. 4a) , indicating that these proteins lack the capacity to bind to either STAT1 or STAT2.
JPV and BeiPV V proteins lack antagonistic activity toward IFN-a signalling
Although paramyxovirus V proteins are generally considered to inhibit IFN signalling via direct interaction with STATs, a number of morbilliviruses inhibit STAT signalling indirectly by inhibiting IFNAR/JAK-mediated STAT activation (Caignard et al., 2007; Chinnakannan et al., 2013 Chinnakannan et al., , 2014 . Since JPV and BeiPV V proteins did not impair IFN-a-dependent STAT1/2 nuclear translocation (above) it seems that STAT phosphorylation/activation is not impaired. However, to examine whether JPV/BeiPV V proteins might otherwise indirectly inhibit STAT1/2 signalling, we co-transfected HEK293T cells with plasmids to express V or control proteins, and plasmids for a type I IFN-dependent luciferase reporter gene assay, before treatment without or with IFN-a and analysis of luciferase activity (Wiltzer et al., 2012 (Wiltzer et al., , 2014 .
In cells expressing GFP alone or the negative control protein NiV W-CTD, IFN-a treatment induced a ca 180-fold increase in relative luciferase activity (Fig. 4b) . As expected, NiV and HeV V proteins significantly inhibited IFNa-dependent luciferase activity compared with GFP (P50.016 and 0.003, respectively; Fig. 4b ) (Rodriguez et al., 2002 (Rodriguez et al., , 2004 . However, expression of JPV V or BeiPV V had no effect. The same result was observed for V fused to GFP as for V fused to a Flag-tag or having no fusion tag (Fig. 4b) . Thus, JPV and BeiPV V proteins do not inhibit IFN-a-mediated activation or signalling by STAT1/2 proteins.
Although representing a conserved interaction formed by V proteins, the regions responsible for STAT1/2 binding differ significantly between paramyxovirus genera/species, for example being localized to the N-terminal domain of NiV and HeV V proteins and C-terminal domain of mumps virus (MuV) and Newcastle disease virus (NDV) V proteins (Audsley & Moseley, 2013) . Multiple sequence alignment of these proteins with the JPV and BeiPV V proteins (Fig. S1 ) indicated differences in both the N-and Cterminal regions that could account for the lack of interaction, including lack of alignment with the NiV V STAT1-binding domain. Determining the precise sequence responsible will form the basis of future investigation. , 16 h) and analysis of luciferase activity. Values for firefly luciferase were normalized to those for Renilla luciferase, and expressed as fold induction compared with non-treated cells expressing GFP alone [mean relative light units (RLU)¡SE; n53 independent assays]. Statistical analysis used a two-tailed, two-sample unequal variance t-test. NS, Not significant; ****P,0.0001.
JPV and BeiPV V proteins do not target rodent STATs
IFN antagonism by some paramyxoviruses is host-speciesspecific, including parainfluenza virus 5 (PIV5) V protein, which targets human but not murine STAT1, and NDV V protein, which supresses IFN expression in chicken but not human cells Park et al., 2003) . Since BeiPV and JPV are rodent viruses, we tested whether this might account for the lack of STAT targeting/antagonism observed in HEK293T and COS-7 cells by expressing JPV and BeiPV V protein in mouse neuroblastoma cell line NA for analysis using the type I IFN-dependent luciferase assay. IFN-a treatment induced a ca 26-fold increase in luciferase activity in GFP-expressing cells, which was significantly inhibited by NiV and HeV V protein expression, but unaffected by JPV or BeiPV V protein (Fig. 5a) . Thus, it appears that JPV and BeiPV V proteins do not impact on IFN-a-dependent STAT1/2 activation or signalling in murine cells.
Consistent with this, we found that, while NiV V protein could significantly (Pv0.0001) inhibit the F n/c for IFNa-activated STAT1 in immunostained NA cells, JPV and BeiPV V protein had no effect, compared with the GFP control (Fig. 5b, c) . This correlated with a lack of interaction of JPV or BeiPV V protein with murine STAT1 in immunoprecipitation assays (Fig. S3) . To further confirm that JPV/BeiPV V proteins do not indirectly affect STAT1 phosphorylation/activation in response to IFN-a, we measured nuclear accumulation of p-STAT1 by counterstaining the NA cells with an antibody specific for the phosphorylated form of STAT1. In non-treated cells, only background levels of staining were detected in the cytoplasm, with no substantial labelling of the nucleus, as expected (Chinnakannan et al., 2013; Lieu et al., 2015) . Following IFN-a treatment, nuclear accumulation of p-STAT1 became apparent in cells expressing GFP, indicated by a significant (Pv0.0001) increase in F n/c for p-STAT1. NiV V protein prevented this accumulation of p-STAT1, but JPV V and BeiPV V protein expression had no effect compared with GFP alone (Fig. 5b, d ).
Together, these data produced in rodent, primate and human cells indicate that JPV/BeiPV V proteins do not interact with STAT1 or STAT2 and lack STAT antagonisticfunction. Among paramyxoviruses examined thus far, only Sendai virus (SeV), Tioman virus (TioPV) and human parainfluenza virus 4 (HPIV4) V proteins have , 0.5 h) before fixation and immunostaining for total STAT1 and p-STAT1 and CLSM imaging. (c, d) Images such as those shown in (b) were analysed to determine the F n/c for total STAT1 (c) or p-STAT1 (d) (mean¡SE, n$25 cells). Statistical analysis used a two-tailed, two-sample unequal variance t-test. NS, Not significant; ***P,0.001; ****P,0.0001. been reported to lack detectable antagonistic activity for type I IFN signalling (Caignard et al., 2013; Gotoh et al., 1999; Nishio et al., 2005) . However, HPIV4 V and TioPV V proteins bind STAT1 and/or STAT2 and, to our knowledge, the STAT1/2 interaction of SeV V has not been tested. Notably, a recent report by Chinnakannan et al. (2013) indicated significant divergence in the capacity of V proteins from different morbillivirus species/strains to bind STATs, whereby all could bind to primate STAT2 to some extent, but some lacked detectable interaction with primate STAT1. Nevertheless, all of the V proteins tested, excepting proteins derived from certain attenuated vaccine strains, could inhibit type I IFN-dependent signalling/transcriptional activation and STAT2 nuclear accumulation. Thus, we believe our study is the first to identify paramyxovirus V proteins lacking both the capacity to block type I IFN signalling and the capacity to bind to STAT1 and/or STAT2, highlighting the atypical nature of BeiPV/JPV V protein. Since mechanisms of STAT antagonism are often characteristic of specific paramyxovirus genera (Audsley & Moseley, 2013; Horvath, 2004) , these findings are consistent with the proposed classification of JPV/BeiPV into a distinct genus.
JPV and BeiPV V proteins inhibit signalling by MDA5
Other than roles in inhibiting STAT1/2 signalling, all paramyxovirus V proteins examined can inhibit induction of type I IFN via an interaction with MDA5 (Andrejeva et al., 2004; Childs et al., 2007) . JPV and BeiPV V proteins contain conserved residues in the C-terminal domain (see Fig. S1 ) that have been implicated in MDA5 binding by the V proteins of several paramyxoviruses (Motz et al., 2013; Ramachandran & Horvath, 2010) . To examine whether JPV/BeiPV V proteins interact with MDA5, we used HEK293T cells co-expressing Flag-MDA5 with V protein for immunoprecipitation analysis (Fig. 6a) , as above. V proteins of JPV, BeiPV and NiV, but not the NiV V N-terminal domain (V-NTD), which lacks the MDA5-binding site (Childs et al., 2007) , could co-precipitate with Flag-MDA5.
To determine if the JPV/BeiPV V proteins inhibit MDA5-dependent activation of the IFN-b promoter, HEK293T cells were co-transfected to express V or control proteins with or without Flag-MDA5, together with the IFN-bGL3 (in which firefly luciferase expression is controlled by the IFN-b promoter) and pRL-TK plasmids. In cells expressing GFP alone, Flag-MDA5 expression increased luciferase expression ca 140-fold compared with cells transfected with pUC18 (empty vector control) (Fig. 6b) . A further increase was observed following stimulation with the MDA5 ligand/ dsRNA analogue polyI : C (InvivoGen) (Fig. 6b) . Expression of NiV V significantly (Pv0.0001) inhibited these responses compared with GFP alone, as expected (Ramachandran & Horvath, 2010) , and expression of JPV or BeiPV V resulted in comparable inhibition (Fig. 6b) . Thus, in spite of clear divergence from NiV, HeV and most other paramyxoviruses Values for firefly luciferase were normalized to those for Renilla luciferase and expressed as fold induction compared with non-treated cells expressing GFP (mean RLU¡SE; n53 independent assays). Statistical analysis used a two-tailed, two-sample unequal variance t-test. ****P,0.0001. with respect to STAT1/2 antagonist function, the JPV and BeiPV V proteins have substantial antagonistic activity toward MDA5/type I IFN induction.
In summary, we have shown that JPV and BeiPV generate edited P gene mRNA that encodes V protein, but that this protein lacks interaction with STAT1/2 and antagonist function toward type I IFN signalling. In spite of this, our infection studies indicate that JPV and BeiPV can inhibit STAT1 responses to IFN-a, suggesting that alternative proteins might function as IFN antagonists for these viruses, including small hydrophobic (SH) and/or transmembrane (TM) proteins, which are encoded by genes present in JPV and BeiPV but absent from most other members of the subfamily Paramyxovirinae (Jack et al., 2005 (Jack et al., , 2008 Li et al., 2006) . The SH protein of JPV, in common with that of the rubulaviruses PIV5 and MuV, can inhibit TNF-a production (Li et al., 2011) , suggestive of roles in immune evasion, although roles in IFN antagonism have not been examined. TM is thus far unique to the proposed jeilongviruses and its function is currently unknown (Jack et al., 2008; Li et al., 2011) . Alternatively, BeiPV/JPV might use additional P-gene-encoded proteins such as P and W, which are reported to have IFN-antagonist function in NiV and HeV, or C protein(s), which are generated from alternate P gene ORFs and target STATs in respiroviruses (Nanda & Baron, 2006; Ohno et al., 2004; Röthlisberger et al., 2010; Shaw et al., 2004) .
Of note, our finding that V-MDA5 targeting is conserved among these otherwise divergent viruses indicates this function is of fundamental importance to paramyxovirus infection. Viral immune evasion has long been recognized as a potential target for the development of novel antivirals/live-attenuated vaccines, and a number of recent studies have demonstrated critical roles of IFN antagonism in viral infection/disease (Devaux et al., 2011; Manokaran et al., 2015; Schaap-Nutt et al., 2010; Wiltzer et al., 2014) . Thus, our data suggest that the V-MDA5 interaction may represent a potent antiviral target against a broad spectrum of paramyxoviruses.
METHODS
Cell lines and viruses. Cell lines were routinely cultured at 37 uC with 5 % CO 2 in Dulbecco's modified Eagle's medium (Vero, COS-7, HEK293T and BHK), Eagle's minimal essential medium (HeLa) or Roswell Park Memorial Institute medium (NA) supplemented with 10 % FBS. Viruses were propagated in Vero cells and clarified by centrifugation before storage at 280 uC. Viruses used were: BeiPV (GenBank accession no. DQ100461), JPV (GenBank GenBank accession no. AY900001), MenPV (accession no. AF326114) and MprPV (GenBank accession no. EF095490).
Expression constructs and transfection. To generate constructs for mammalian cell expression of GFP-fused V or derivatives, edited (+G, generated by overlap PCR mutagenesis of P gene cDNA) P genes were inserted into the pEGFP-C1 plasmid (Clontech) using Xho I/ Eco RI (JPV V), Bgl II/Eco RI (BeiPV V) or Bgl II/Bam HI (HeV V). The BeiPV V sequence used corresponds to the original cDNA sequence reported by Magoffin et al. (2007) , but differs from available GenBank sequences by a single residue substitution (T135M); neither T nor M is conserved at this position in JPV V protein (Fig. S1 ), indicating that it is not critical to V protein function. For expression of Flag-tagged JPV V protein, the V coding sequence was excised from pEGFP-C1 JPV V using Bsp EI/Eco RI sites and inserted into pCAG-OSF (Bajorek et al., 2009 ) vector using Xma I/Eco RI. For expression of non-tagged BeiPV V, the coding sequence was inserted into pD EGFP-C (Oksayan et al., 2012b) using Bgl II/Eco RI.
Negative control proteins NiV W-CTD (residues 390-450), NiV V-CTD (residues 390-456) and NiV V-NTD (residues 1-389) were amplified from pCAGGS-NiV W and pCAGGS-NiV V (Park et al., 2003) (kindly provided by C. Basler, Mount Sinai School of Medicine, New York, NY, USA) and cloned into the Bgl II/Bam HI sites of pEGFP-C1. The constructs for expression of GFP-fused NiV V (Joubert et al., 2014) and Flag-MDA5 (human) (Rothenfusser et al., 2005) are described elsewhere.
Luciferase reporter assays used plasmids pRL-TK (Promega), pISREluc (Stratagene) and IFN-bGL3 (Lin et al., 2000) (kindly provided by Rongtuan Lin, McGill University, Quebec, Canada).
Transfections were performed using FuGENE HD (Promega) or Lipofectamine 2000 (Life Technologies) according to the manufacturer's recommendations.
Antibodies. Anti-BeiPV P/V/W antibody was described previously (Li et al., 2006) . Rabbit antiserum against JPV was generated at the CSIRO Australian Animal Health Laboratory (Geelong, Australia). Other antibodies used were: mouse anti-actin (Abcam), mouse anti-a/b tubulin (Cell Signaling), mouse anti-STAT1 (BD Biosciences), goat anti-p-STAT1 (Santa Cruz Biotechnology), rabbit anti-STAT2 (Santa Cruz Biotechnology), mouse anti-GFP (Roche Applied Science) and rabbit OctA-Probe antibody (D-8) (Santa Cruz Biotechnology). Secondary antibodies are described below.
Next-generation sequencing (NGS) of viral gene transcripts.
Vero cells were infected at an m.o.i. of 0.05 for 48 h before total RNA extraction using a Qiagen RNeasy Mini kit. Total cDNA was generated using Superscript III Reverse Transcriptase (Invitrogen) with oligo(dT) primers according to the manufacturers protocol. cDNA for the P gene was then amplified (25 cycles) with specific primers (Table S1 ) using the Expand High Fidelity PCR System (Roche). Gel-purified 1 kb amplicons for BeiPV, MprPV, MenPV and JPV P genes were used to prepare Illumina Nextera XT dual-indexed libraries for NGS on the Illumina MiSeq platform with 150 bp paired-end read output. Unreliable data and Nextera XT adaptor sequences were removed using the Real-Time Analysis and MiSeq Reporter software, respectively. NGS data were analysed using CLC Genomics Workbench software version 5.5.1. Trimmed reads were mapped to the corresponding paramyxovirus genomic RNA sequence using default parameters of the 'map reads to reference' algorithm. The read mapping output was used for detection of deletion-insertion polymorphisms (DIPs) using the 'quality variant detection' algorithm with the minimum variant frequency set at 0.1 % and requirement for presence of both forward and reverse reads. Each DIP within the relevant region was cross-matched to the mapping output to manually examine the context, i.e. poly(G) nucleotides corresponding to the editing sites of JPV (nt 703-704), BeiPV (nt 703-704), and . Ambiguous DIPs that were not insertions or were a combination of G and another base were excluded. Sequence reads containing additional G nucleotides within the editing region were calculated as a percentage of total sequence reads to determine editing frequencies. BeiPV at an m.o.i. of 0.1 for 24 h, or were transfected with plasmid DNA to express GFP-fusion proteins for 6 h. Cells were then serumstarved (0.5 % FBS for 16 h, followed by serum-free medium for 1 h) before treatment with 2000 U ml 21 Universal type I IFN-a (PBL IFN Source) for 0.5 h. Cells were fixed in 4 % paraformaldehyde (37 uC, 20 min) and permeablized using 0.2 % v/v Triton-X (10 min) or 90 % methanol (5 min) in PBS, before immunostaining for STAT1, p-STAT1 or STAT2. Secondary antibody staining used Alexa Fluor-conjugated antibodies (Molecular Probes): 488-conjugated anti-rabbit IgG (BeiPV and JPV), 568-conjugated anti-mouse IgG (STAT1), 568-conjugated anti-rabbit IgG (STAT2), or 568-conjugated anti-goat IgG and 647-conjugated anti-mouse IgG (for STAT1 and p-STAT1 dual-labelled samples). To detect the nucleus, cells were stained with 40 mg Hoechst (Sigma Aldrich) ml 21 and mounted onto glass slides using Mowiol mounting medium (Calbiochem), or were mounted onto glass slides using ProLong Gold antifade mounting reagent with DAPI (Life Technologies).
Immunoprecipitation. Co-immunoprecipitation was performed using HEK293T cells or MEF cells transfected with plasmid to express GFP or GFP-V proteins; in some samples cells were co-transfected with plasmid to express Flag-MDA5. Cells were lysed before immunoprecipitation using GFP-Trap (ChromoTek) according to the manufacturer's instructions. Total cell lysate (input) and immunoprecipitate were separated by 10 % SDS-PAGE for Western transfer and immunoblotting.
CLSM and image analysis. CLSM was performed using an Olympus Fluoview FV1000 inverted microscope (|60 oil immersion objective) or Leica SP5 inverted microscope (|100 oil immersion objective). For analysis of digitized CLSM images, FIJI (v1.48q) software was used to calculate the nuclear/cytoplasmic fluorescence ratio (F n/c ) corrected for background fluorescence as described previously (Moseley et al., 2009; Oksayan et al., 2012a; Wiltzer et al., 2014) . Mean F n/c was calculated using data from i25 cells for each condition.
Luciferase reporter assays. To measure type I IFN/STAT1/ 2-dependent signalling, HEK293T or NA cells grown to 70 % confluence in 12-well cell culture plates were co-transfected with 0.5 mg plasmid encoding GFP, GFP-V proteins or untagged/Flag-tagged V proteins, 0.5 mg pISRE-luc (wherein firefly luciferase expression is under the control of a type I IFN/STAT1/2-dependent ISREcontaining promoter) and 0.08 mg pRL-TK (from which Renilla luciferase is constitutively expressed). At 8 h post-transfection, cells were treated without or with 2000 U ml 21 Universal type I IFN-a (PBL IFN source) for 16 h before lysis (1| passive lysis buffer; Invitrogen) and analysis of luciferase expression in a dual luciferase assay, as described previously (Wiltzer et al., 2012 (Wiltzer et al., , 2014 .
To measure MDA5 activation of the IFN-b promoter, HEK293T cells were co-transfected to express GFP or GFP-fused V proteins as above, with 0.5 mg IFN-bGL3 (in which firefly luciferase is under the control of the IFN-b promoter) and 0.08 mg pRL-TK. To stimulate IFN-bGL3, cells were co-transfected with 0.25 mg Flag-MDA5 plasmid; for control samples, cells were co-transfected with an equivalent amount of pUC18 (empty vector). Luciferase activity was measured 40 h post-transfection, as above. In some samples, cells were transfected with 5 mg polyI : C (InvivoGen) 24 h after plasmid transfections.
